Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Baricitinib can help improve hair loss and skin color issues in people with Down syndrome.

CTP-543 is generally safe for treating alopecia areata.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

JAK inhibitors helped treat hair loss in two people with Down syndrome.

Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.

Deuruxolitinib is approved to treat severe alopecia areata in adults.

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.

TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.

JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.

Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.

Baricitinib effectively treats certain skin conditions but may have serious side effects.

Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.

Janus kinase inhibitors are effective and safe for treating Alopecia Areata.

JAK inhibitors show promise for treating Alopecia Areata, while statins are not recommended.

JAK inhibitors are effective and safe for treating severe alopecia areata.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.

Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.

The PDGF/PDGFR pathway is a potential drug target with mixed success in treating various diseases, including some cancers and fibrosis.

Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.

Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.

Baricitinib shows promise for treating alopecia areata with mild side effects.

Many patients on new leukemia drugs had mild to moderate skin reactions.

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

JAK inhibitors can help treat alopecia areata but have risks and high costs.

The FDA approved a new Pfizer drug for hair loss in teens.

Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.